Stakeholders Urge Caution In Medicare Coverage Of Carotid Stenting
This article was originally published in The Gray Sheet
Executive Summary
Opponents of expanded Medicare coverage for carotid artery stenting procedures fear that reimbursement would lead to overutilization and disrupt enrollment in clinical trials that could help collect more detailed outcomes evidence
You may also be interested in...
New Data Gives Carotid Stenting A Third Shot At Broader Medicare Coverage
CMS is again considering whether to expand Medicare coverage for carotid artery stenting
Reimbursement, Not Off-Label Use, May Be Hindering Carotid Stent Trials
Enrollment of randomized trials of carotid stents in low-risk patients has been slow because many doctors have an economic incentive to prevent their patients from being randomized, according to Kenneth Rosenfield, M.D., Massachusetts General Hospital
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.